Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $22.1052W HIGH $45.14
Volume
231.86 K
Value Traded
31.03 M
Short % Float
14.5%
Days to Cover
3.8
-0.99%Week
-6.72%1 Month
-17.6%3 Month
-12.73%6 Month
+9.75%5 Year
-96.5%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
2.32 B
EPS (TTM)
-3.83
P/E Ratio
-
Ent. Value
1.60 B
Total Shares
78.50 M
Float Shares
75.92 M
Insiders
3.32%
Institutions
105.71%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
CLDX Catalyst Timeline
Dated clinical, regulatory and corporate events for Celldex Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Celldex Therapeutics, Inc.
1012Total events
8Upcoming
175Tier-1 (high impact)
2008 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Topline ReadoutBarzolvolimabClinical Data
Celldex reports positive topline results from Phase 3 EMBARQ-CSU1 in CSU
chronic spontaneous urticaria (CSU)source ↗
▲Primary Endpoint MetBarzolvolimabClinical Data
EMBARQ-CSU1 met primary endpoint of mean change from baseline in UAS7 at Week 12
chronic spontaneous urticaria (CSU)source ↗
▲Secondary Endpoint DataBarzolvolimabClinical Data
All key secondary endpoints met in both EMBARQ-CSU trials at Week 12
chronic spontaneous urticaria (CSU)source ↗
▲Safety Data UpdateBarzolvolimabClinical Data
Barzolvolimab well tolerated with favorable safety profile through 24 weeks
chronic spontaneous urticaria (CSU)source ↗
●Quarterly UpdateCorporate
Celldex to host webcast/conference call to discuss EMBARQ-CSU results
▲Enrollment CompleteBarzolvolimabTrial
Enrollment completed in Phase 3 CSU program
chronic spontaneous urticariasource ↗
●Enrollment UpdateBarzolvolimabTrial
Phase 3 study actively enrolling
cold urticaria and symptomatic dermographismsource ↗
▼Program DiscontinuationBarzolvolimabCorporate
Discontinuing Phase 2 PN study
prurigo nodularissource ↗
●Trial InitiationCDX-622Trial
Expansion into additional indications planned
allergic rhinitis and food allergysource ↗
▼Topline ReadoutBarzolvolimabClinical Data
Phase 2 topline results in prurigo nodularis
prurigo nodularissource ↗
▼Trial DiscontinuedBarzolvolimabTrial
Phase 2 study in prurigo nodularis discontinued
prurigo nodularissource ↗
▼Topline ReadoutBarzolvolimabClinical Data
Topline data presented in July 2026; did not meet endpoints
prurigo nodularissource ↗
▲Oral PresentationCDX-622Presentation
Positive first-in-human results from Phase 1 study of CDX-622 presented at EAACI Annual Meeting
healthy participantssource ↗
◆Oral PresentationBarzolvolimabPresentation
Psychometric Validation of the Worst Itch Numeric Rating Scale (WI-NRS) as a Patient-Reported Outcome (PRO) in Cold Urticaria: Data from a Clinical Trial of Barzolvolimab
cold urticaria (ColdU)source ↗
▲Oral PresentationPresentation
Non-human primate data presented at EMBRN validating soluble SCF targeting approach
▲Oral PresentationBarzolvolimabPresentation
Long-term results presented at EAACI Annual Meeting
chronic spontaneous urticariasource ↗
▲Oral PresentationCDX-622Presentation
First-in-human data presented in June 2026
mast cell mediated diseasessource ↗
▲Enrollment CompleteBarzolvolimabTrial
Enrollment completed six months ahead of guidance in Phase 3 CSU studies
chronic spontaneous urticariasource ↗
◆Enrollment UpdateBarzolvolimabTrial
Phase 3 ColdU and SD study actively enrolling
cold urticaria and symptomatic dermographismsource ↗
▲Enrollment CompleteCDX-622Trial
Enrollment complete in Phase 1 healthy volunteer study
healthy volunteerssource ↗
◆Oral PresentationPresentation
Fireside chat at H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference
▼Equity OfferingCorporate
Closing of public offering of common stock and full exercise of underwriters' option
◆Topline ReadoutBarzolvolimabClinical Data
Topline data expected from Phase 2 PN study
prurigo nodularissource ↗
▲Poster PresentationBarzolvolimabPresentation
Poster presentation of prolonged and enhanced quality of life data from Phase 2 CSU study at AAD 2026
chronic spontaneous urticariasource ↗
▲Poster PresentationBarzolvolimabPresentation
Late breaking poster presentation of retreatment data from Phase 2 OLE at AAAAI 2026
Cold Urticaria (ColdU) and Symptomatic Dermographism (SD)source ↗
◆Late-BreakerBarzolvolimabPresentation
Retreatment with Barzolvolimab Leads to Rapid Improvement in Urticaria Control After Symptom Recurrence in Chronic Inducible Urticaria
chronic inducible urticaria (ColdU and SD)source ↗
▲Oral PresentationBarzolvolimabPresentation
Treatment with Barzolvolimab Improves Urticaria Control and Quality of Life in Patients with Chronic Inducible Urticaria (20 week analysis) presented at AAAAI 2026
chronic inducible urticaria (cold urticaria and symptomatic dermographism)source ↗
◆Poster PresentationBarzolvolimabPresentation
Treatment with Barzolvolimab Improves Urticaria Control and Quality of Life in Patients with Chronic Inducible Urticaria
chronic inducible urticaria (ColdU and SD)source ↗
▲Enrollment CompleteBarzolvolimabTrial
Enrollment completed in EMBARQ-CSU1
chronic spontaneous urticariasource ↗
◆Oral PresentationPresentation
Celldex management to participate in fireside chats at upcoming investor conferences
▲Enrollment CompleteBarzolvolimabTrial
Enrollment completed in global Phase 3 CSU program (EMBARQ-CSU1 and EMBARQ-CSU2)
chronic spontaneous urticariasource ↗
◆Oral PresentationBarzolvolimabPresentation
OLE data expected to be presented in Q1 2026
cold urticaria and symptomatic dermographismsource ↗
▲Trial InitiationBarzolvolimabTrial
Initiation of global Phase 3 trial for barzolvolimab in ColdU and SD
cold urticaria and symptomatic dermographismsource ↗
▲Primary Endpoint MetBarzolvolimabClinical Data
Phase 2 study met primary endpoint with high statistical significance at Week 12
cold urticaria and symptomatic dermographismsource ↗
▲Full ResultsBarzolvolimabClinical Data
Phase 2 full results: sustained responses through Week 20
cold urticaria and symptomatic dermographismsource ↗
◆Oral PresentationPresentation
Management to participate in fireside chat at Piper Sandler 37th Annual Healthcare Conference
●Trial InitiationBarzolvolimabTrial
Phase 3 study initiated in ColdU and SD
cold urticaria and symptomatic dermographismsource ↗
▲Enrollment CompleteBarzolvolimabTrial
Enrollment completed in Phase 3 CSU studies six months ahead of guidance
chronic spontaneous urticariasource ↗
◆Oral PresentationPresentation
Management to participate in fireside chat at Stifel 2025 Healthcare Conference
▲Topline ReadoutBarzolvolimabClinical Data
Barzolvolimab demonstrates clinical benefit in cold urticaria and symptomatic dermographism
cold urticariasource ↗
Past FDA Catalysts and PDUFA Decisions
How CLDX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-06-14 | CDX-622 | Phase 1 data readout | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
5
Drugs Scored
rNPV / MCap
Top Drug
Top 9%
Small Cap(rank 60 of 657)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Barzolvolimab Monoclonal antibodyNCT06445023 | Chronic Spontaneous Urticaria | Phase 3 | ACTIVE NOT_RECRUITING | 3,517 | Apr 1, 2027 | ||||||
| Barzolvolimab Monoclonal antibodyNCT06727552 | Atopic Dermatitis | Phase 2 | ACTIVE NOT_RECRUITING | 131 | Dec 1, 2026 | ||||||
| Barzolvolimab Monoclonal antibodyNCT06366750 | Prurigo Nodularis | Phase 2 | ACTIVE NOT_RECRUITING | 140 | Mar 1, 2027 | ||||||
| CDX-622 Small moleculeNCT07330778 | Mild to Moderate Asthma | Phase 1 | RECRUITING | 12 | Mar 1, 2027 | ||||||
| Barzolvolimab Monoclonal antibodyNCT05405660 | Chronic Inducible Urticaria | Phase 3 | COMPLETED | 436 | Sep 12, 2025 | ||||||
| Barzolvolimab Monoclonal antibodyCompletedNCT05774184 | Eosinophilic Esophagitis | Phase 2 | COMPLETED | 86 | Jan 23, 2026 | ||||||
| CDX-0159 Monoclonal antibodyCompletedNCT04538794 | Chronic Spontaneous Urticaria | Phase 1 | COMPLETED | 45 | Jan 17, 2023 | ||||||
| CDX-0159 Monoclonal antibodyCompletedNCT04548869 | Cold Urticaria | Phase 1 | COMPLETED | 41 | May 12, 2023 | ||||||
| CDX-527 Small moleculeCompletedNCT04440943 | Non-small Cell Lung Cancer | Phase 1 | COMPLETED | 27 | Apr 6, 2023 | ||||||
| CDX-585 Small moleculeCompletedNCT05788484 | Non-small Cell Lung Cancer | Phase 1 | COMPLETED | 20 | May 21, 2025 | ||||||
| CDX-1140 Small moleculeCompletedNCT03329950 | Melanoma | Phase 1 | COMPLETED | 154 | Sep 13, 2022 |
Clinical Trial Results
Readouts, endpoints and source filings for every CLDX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| barzolvolimab | chronic spontaneous urticaria (CSU) | Phase 3 | 2026-09-22 | clinically meaningful and statistically significant improvements in disease activityRead More | Celldex Announces Positive Results from Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 Studies of Barzolvolimab Which Met Primary and All Key Secondary EndpointsRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Lawver Teri LOfficer (SVP & Chief Commercial Officer) | Grant/Award | 90,000 90,000 held | $0.00 | 06/25/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in CLDX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Kynam Capital Management, LP | 10.9 % (-4.4 %) | 198.07 M | 5.32 M | -8.86% ( -517.66 K) |
CLDX Institutional Ownership Trends
CLDX Short Interest
Shares sold short, counted twice a month.
14.5%
Short % of Float
of tradable shares sold short
11.0M
Shares Sold Short
+22.9% vs prior count
3.8 Moderate
Days to Cover
trading days of normal volume to buy every short share back
2.9M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How CLDX ranks across every disease it competes in
Competitive Position is a premium feature
See how CLDX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCLDX News
CLDX▼ -11.6%on this news
Celldex Announces Positive Results from Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 Studies of Barzolvolimab Which Met Primary and All Key Secondary Endpoints
Celldex announced positive results from its Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 trials, showing that barzolvolimab met all primary and secondary endpoints for chronic spontaneous urticaria (CSU). The treatment demonstrated significant efficacy and was well-tolerated over 24 weeks. A Biologics License Application (BLA) is anticipated in 2027, with ongoing trials extending to 52 weeks.
Read more →CLDXCelldex to Present at Upcoming Investor Conference
Celldex (NASDAQ:CLDX) will participate in a fireside chat at the Cantor Global Healthcare Conference on September 10, 2026. The presentation will be available via webcast, with replays accessible for 90 days post-event. The company continues to advance its mission of developing innovative antibody-based therapies for immune-related disorders.
Read more →CLDXCelldex Reports Second Quarter Financial Results and Provides Corporate Update
Celldex reported its Q2 2026 financial results, highlighting ongoing Phase 3 trials for barzolvolimab in chronic spontaneous urticaria and cold urticaria. The company also announced positive Phase 1 results for its bispecific antibody CDX-622. Despite a significant net loss and reduced revenues, Celldex maintains a strong cash position to support its operations through 2028.
Read more →CLDXCelldex Reports Results from Phase 2 Study of Barzolvolimab in Prurigo Nodularis
Celldex's Phase 2 study of barzolvolimab in prurigo nodularis did not meet its primary or key secondary endpoints, leading to the discontinuation of the study. Despite showing a favorable safety profile and significant mast cell depletion, the treatment failed to improve symptoms compared to placebo. The company remains focused on other indications where barzolvolimab has shown promise.
Read more →CLDX▼ -7.6%on this newsshared move
Celldex Announces Planned Transition of Chief Financial Officer
Celldex announced the planned retirement of CFO Sam Martin in 2027 after serving since 2017. The company is searching for a new CFO while ensuring a smooth transition. Martin expressed pride in the company's achievements and confidence in its future, particularly with upcoming Phase 3 trial data for barzolvolimab.
Read more →CLDXCelldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting
Celldex presented long-term results from a Phase 2 study of barzolvolimab at the EAACI Annual Meeting, showing significant and sustained improvements in angioedema for patients with chronic spontaneous urticaria (CSU). Seven months after treatment, 64% of patients remained angioedema-free. The findings support ongoing Phase 3 trials, with topline data expected in Q4 2026.
Read more →CLDXCelldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting
Celldex presented positive Phase 1 results for CDX-622, a bispecific antibody targeting soluble SCF and TSLP, at the EAACI Annual Meeting. The study showed significant reductions in serum tryptase, indicating effective mast cell depletion, and was well-tolerated across all doses. The findings suggest a promising avenue for treating inflammatory diseases.
Read more →CLDXCelldex Announces Multiple Upcoming Presentations from Leading Mast Cell Targeting Pipeline at the Upcoming 2026 European Academy of Allergy and Clinical Immunology Annual Congress
Celldex announced three upcoming presentations at the EAACI Annual Congress in Istanbul, showcasing their mast cell targeting pipeline. The presentations will include results from the barzolvolimab program in chronic spontaneous urticaria and a late-breaking poster on the bispecific antibody CDX-622. These findings highlight the potential of these therapies in treating inflammatory conditions.
Read more →CLDXCelldex Reports First Quarter Financial Results and Provides Corporate Update
Celldex (NASDAQ: CLDX) reported its first quarter financial results for 2026, highlighting the early completion of enrollment in two Phase 3 studies for barzolvolimab. The company raised $345 million from a public offering and is anticipating multiple data readouts in 2026, indicating strong potential for its pipeline. Despite these positive developments, Celldex experienced an increase in net loss and a significant drop in revenue compared to the previous year. The company remains focused on advancing its clinical programs and preparing for commercialization.
Read more →CLDXCelldex to Present at Upcoming April 2026 Investor Conference
Celldex (NASDAQ:CLDX) will participate in a fireside chat at H.C. Wainwright's 4th Annual Inflammatory Skin Disease Virtual Conference on April 14, 2026. The event will be accessible via webcast, with replays available for 90 days. This participation highlights Celldex's commitment to engaging with investors and discussing its advancements in immunology.
Read more →CLDXCelldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Celldex Therapeutics has completed its public offering of 11,896,750 shares of common stock, raising around $345 million in gross proceeds. This offering included full exercise of the underwriters' option for an additional 1,551,750 shares, reflecting strong market interest. All shares were sold by Celldex, utilizing a previously filed registration statement with the SEC. The successful closure of this offering is expected to bolster the company's finances as it advances its therapeutic pipeline.
Read more →CLDXCelldex Announces Pricing of $300 Million Public Offering of Common Stock
Celldex Therapeutics has announced a public offering of 10,345,000 shares at $29.00 each, aiming to raise approximately $300 million. The proceeds will support ongoing commercial activities for barzolvolimab and further development of its product candidates. The offering is expected to close around April 6, 2026, pending customary conditions.
Read more →CLDXCelldex Announces Proposed Public Offering of Common Stock
Celldex Therapeutics has announced a proposed public offering of its common stock to fund various initiatives, including the commercial launch of barzolvolimab for CSU treatment. The offering includes a 30-day option for underwriters to purchase additional shares. The final terms will be determined by market conditions, with no guarantees on completion.
Read more →CLDXCelldex Presents Positive Data from Phase 2 Chronic Spontaneous Urticaria and Phase 2 Cold Urticaria and Symptomatic Dermographism Studies Demonstrating Rapid, Profound and Durable Improvements in Patient Quality of Life at AAD 2026
Celldex presented positive Phase 2 trial data for barzolvolimab, highlighting significant improvements in quality of life for patients with chronic spontaneous urticaria and cold urticaria. The data, showcased at the AAD Annual Meeting, demonstrated that a majority of patients experienced symptom-free responses and sustained benefits even after treatment cessation. This positions barzolvolimab as a promising treatment option in its class.
Read more →CLDXCelldex Presents Additional Positive Data from Phase 2 Chronic Spontaneous Urticaria (CSU) and Phase 2 Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Studies Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026
Celldex has presented promising data from Phase 2 trials of barzolvolimab for chronic spontaneous urticaria (CSU), cold urticaria (ColdU), and symptomatic dermographism (SD) at the AAAAI Annual Meeting. The results indicate sustained efficacy even after treatment cessation, alongside improved patient quality of life. Barzolvolimab's unique mechanism targets mast cells, potentially transforming treatment options for these conditions.
Read more →CLDXCelldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026
Celldex presented positive Phase 2 data on barzolvolimab at the AAAAI 2026 meeting, demonstrating that retreatment leads to rapid improvement in patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD). The study showed that 62% of ColdU patients and 60% of SD patients achieved a complete response after retreatment, comparable to initial treatment results. Barzolvolimab's mechanism targets mast cells, supporting its profile as a best-in-class treatment for chronic urticarias.
Read more →CLDXCelldex Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
Celldex reported its financial results for Q4 and the year ending December 31, 2025, highlighting strong progress in its clinical programs, particularly for barzolvolimab. The company completed enrollment in its Phase 3 CSU studies ahead of schedule and anticipates multiple important data readouts in 2026. However, it also reported a significant net loss and a decrease in revenue compared to the previous year.
Read more →CLDX▲ +24.1%on this newsshared move
Celldex Completes Enrollment in Global Phase 3 Studies (EMBARQ-CSU1 and EMBARQ-CSU2) of Barzolvolimab in Chronic Spontaneous Urticaria
Celldex has completed enrollment in its global Phase 3 studies of barzolvolimab for chronic spontaneous urticaria, with 1,939 patients enrolled across 43 countries. The studies aim to establish the efficacy and safety of barzolvolimab in patients unresponsive to antihistamines. Results are expected later this year, highlighting the treatment's potential to address significant unmet needs in CSU.
Read more →About Celldex Therapeutics, Inc.
Headquarters53 FRONTAGE ROAD, HAMPTON, NJ, 08827
BIOPHARMAWATCH ELITE PLUS
Trade the next CLDX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime